Masataka Sata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masataka Sata has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Hirotsugu Yamada
Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
23 shared publications - Michio Shimabukuro
Department of Diabetes, Endocrinology, and Metabolism, Fukushima Medical University School of Medicine , Fukushima 960-1295
17 shared publications - Kenya Kusunose
Department of Cardiovascular Medicine, Nephrology, and Neurology, University of the Ryukyus, Okinawa, Japan
16 shared publications - Daiju Fukuda
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences
10 shared publications Takeshi Soeki
Department of Community Medicine and Medical Science Tokushima University Graduate School of Biomedical Sciences Tokushima Japan
10 shared publications- Atsushi Tanaka
Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501
9 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (8) , 1201-1204
The Circulation Reports Official Impact Factor and the Most Frequently Cited Papers in 2025
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 10 August 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (8) , 1201-1204
Open AccessThe Circulation Reports Official Impact Factor and the Most Frequently Cited Papers in 2025
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 12 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (13)
Emerging roles of the cGAS/STING pathway in cardiovascular diseases
Cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity worldwide, highlighting the need for novel therapeutic approaches. Inflammation plays a key role in CVD pathogenesis, and accumulating evidence has implicated the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway in this process. The cGAS/STING pathway recognizes both non-self- and self-DNA, including mitochondrial and nuclear DNA, to activate its downstream proinflammatory signaling molecules, including TANK-binding kinase 1, IFN regulatory factor 3, and NF-κB. Various pathological stressors have been shown to induce self-DNA release into the cytosol and bloodstream from damaged cells in the cardiovascular system, indicating that circulating cell-free DNA is a useful biomarker of CVDs; however, how this contributes to the inflammatory signaling, cell death, and fibrosis that characterize CVDs remains unclear. Here, we discuss the current understanding on the roles of self-DNA and the cGAS/STING pathway in the pathophysiology of CVDs and the therapeutic potential of targeting this pathway.
- 12 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (13)
Open AccessEmerging roles of the cGAS/STING pathway in cardiovascular diseases
Cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity worldwide, highlighting the need for novel therapeutic approaches. Inflammation plays a key role in CVD pathogenesis, and accumulating evidence has implicated the cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway in this process. The cGAS/STING pathway recognizes both non-self- and self-DNA, including mitochondrial and nuclear DNA, to activate its downstream proinflammatory signaling molecules, including TANK-binding kinase 1, IFN regulatory factor 3, and NF-κB. Various pathological stressors have been shown to induce self-DNA release into the cytosol and bloodstream from damaged cells in the cardiovascular system, indicating that circulating cell-free DNA is a useful biomarker of CVDs; however, how this contributes to the inflammatory signaling, cell death, and fibrosis that characterize CVDs remains unclear. Here, we discuss the current understanding on the roles of self-DNA and the cGAS/STING pathway in the pathophysiology of CVDs and the therapeutic potential of targeting this pathway.
- Open Access
- 9 January 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (1) , 1-3
Circulation Reports Is Entering 8th Year With a Rising Impact Factor
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 9 January 2026
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (1) , 1-3
Open AccessCirculation Reports Is Entering 8th Year With a Rising Impact Factor
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043266
Impact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device
Background: Risk stratification of patients with cardiogenic shock (CS) is of considerable importance. We aimed to test the utility of the Society for Cardiovascular Angiography and Intervention shock staging system recently refined by the CS Working Group in an Asian population and to investigate its association with in‐hospital adverse events. Methods: From the Japanese nationwide registry of Impella, the patients with CS who successfully received Impella support between February 2020 and December 2023 were included and assigned to any stage according to the CS Working Group–refined Society for Cardiovascular Angiography and Intervention staging system. We set the primary end point as in‐hospital death and explored it within each stage, with stage B as a reference. Results: In total, 4643 patients were analyzed (median age, 69 years; women, 23.3%; CS due to acute myocardial infarction, 61.7%), and 122, 588, 1905, and 2058 patients were in stages B, C, D, and E, respectively. After adjustment with potential confounders, stage C had no significant difference in in‐hospital death (odds ratio, 1.12 [95% CI, 0.69–1.80]; P =0.653). However, with adjusted analysis, stages D and E had a significantly higher rate of in‐hospital death (stage D: odds ratio, 2.41 [95% CI, 1.55–3.77]; P P <0.001). Conclusions: The CS Working Group–refined Society for Cardiovascular Angiography and Intervention staging system at baseline has a satisfactory association with in‐hospital death in the more progressive stage; however, the system seems to have a lower power in the earlier phase of CS. Further investigation is warranted to establish a more accurate staging system.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e043266
Open AccessImpact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device
Background: Risk stratification of patients with cardiogenic shock (CS) is of considerable importance. We aimed to test the utility of the Society for Cardiovascular Angiography and Intervention shock staging system recently refined by the CS Working Group in an Asian population and to investigate its association with in‐hospital adverse events. Methods: From the Japanese nationwide registry of Impella, the patients with CS who successfully received Impella support between February 2020 and December 2023 were included and assigned to any stage according to the CS Working Group–refined Society for Cardiovascular Angiography and Intervention staging system. We set the primary end point as in‐hospital death and explored it within each stage, with stage B as a reference. Results: In total, 4643 patients were analyzed (median age, 69 years; women, 23.3%; CS due to acute myocardial infarction, 61.7%), and 122, 588, 1905, and 2058 patients were in stages B, C, D, and E, respectively. After adjustment with potential confounders, stage C had no significant difference in in‐hospital death (odds ratio, 1.12 [95% CI, 0.69–1.80]; P =0.653). However, with adjusted analysis, stages D and E had a significantly higher rate of in‐hospital death (stage D: odds ratio, 2.41 [95% CI, 1.55–3.77]; P P <0.001). Conclusions: The CS Working Group–refined Society for Cardiovascular Angiography and Intervention staging system at baseline has a satisfactory association with in‐hospital death in the more progressive stage; however, the system seems to have a lower power in the earlier phase of CS. Further investigation is warranted to establish a more accurate staging system.
- Open Access
- 10 July 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (7) , 497-499
Circulation Reports Has Received Its Long-Awaited Impact Factor in Its Seventh Year of Publication!!
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 10 July 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (7) , 497-499
Open AccessCirculation Reports Has Received Its Long-Awaited Impact Factor in Its Seventh Year of Publication!!
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e038071
Successful or Uncomplicated Use of Drug‐Coated Balloon Versus Drug‐Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan
Background: Randomized trials demonstrated that drug‐coated balloon (DCB) was not inferior to drug‐eluting stent (DES) for acute coronary syndrome (ACS). However, generalizability in clinical settings remains unclear. The present study compared the outcomes of DCB and DES strategies in percutaneous coronary intervention for ACS within a nationwide procedure‐based registry. Methods and Results: This was a retrospective analysis of a cohort study from a prospective, nationwide registry between January 2017 and December 2020 in Japan, focusing on patients with ACS who underwent DCB or DES for a single de novo lesion. Patients who required bailout stenting after treatment with DCB were excluded from the analysis. The 1‐year incidence of all‐cause mortality, cardiovascular death, noncardiovascular death, nonfatal ACS, stroke, and major bleeding events was compared. A subgroup analysis included lesion‐based and ST‐elevation myocardial infarction/non‐ST‐elevation ACS stratifications. Among 5212 propensity score–matched patients with ACS, no significant differences were observed in the 1‐year incidence of all‐cause mortality (4.5% versus 4.6%, hazard ratio [HR], 0.92 [95% CI, 0.72–1.19]); cardiovascular death (2.5% versus 2.5%, HR, 0.90 [95% CI, 0.64–1.26]); noncardiovascular death (2.0% versus 2.1%, HR, 0.96 [95% CI, 0.65–1.42]); or nonfatal ACS (1.7% versus 2.0%, HR, 1.04 [95% CI, 0.70–1.54]) between DCB and DES. DCB was associated with a higher incidence of stroke (0.8% versus 0.3%, HR, 2.33 [95% CI, 1.06–5.08]) and lower incidence of major bleeding events (1.4% versus 2.3%, HR, 0.65 [95% CI, 0.43–0.99]); however, these results were not reproduced in the subgroup analysis. Conclusions: The DCB strategy for successfully treated ACS cases achieved similar clinical outcomes to DES after 1 year. Further studies with an extended follow‐up are needed to confirm these results.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e038071
Open AccessSuccessful or Uncomplicated Use of Drug‐Coated Balloon Versus Drug‐Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan
Background: Randomized trials demonstrated that drug‐coated balloon (DCB) was not inferior to drug‐eluting stent (DES) for acute coronary syndrome (ACS). However, generalizability in clinical settings remains unclear. The present study compared the outcomes of DCB and DES strategies in percutaneous coronary intervention for ACS within a nationwide procedure‐based registry. Methods and Results: This was a retrospective analysis of a cohort study from a prospective, nationwide registry between January 2017 and December 2020 in Japan, focusing on patients with ACS who underwent DCB or DES for a single de novo lesion. Patients who required bailout stenting after treatment with DCB were excluded from the analysis. The 1‐year incidence of all‐cause mortality, cardiovascular death, noncardiovascular death, nonfatal ACS, stroke, and major bleeding events was compared. A subgroup analysis included lesion‐based and ST‐elevation myocardial infarction/non‐ST‐elevation ACS stratifications. Among 5212 propensity score–matched patients with ACS, no significant differences were observed in the 1‐year incidence of all‐cause mortality (4.5% versus 4.6%, hazard ratio [HR], 0.92 [95% CI, 0.72–1.19]); cardiovascular death (2.5% versus 2.5%, HR, 0.90 [95% CI, 0.64–1.26]); noncardiovascular death (2.0% versus 2.1%, HR, 0.96 [95% CI, 0.65–1.42]); or nonfatal ACS (1.7% versus 2.0%, HR, 1.04 [95% CI, 0.70–1.54]) between DCB and DES. DCB was associated with a higher incidence of stroke (0.8% versus 0.3%, HR, 2.33 [95% CI, 1.06–5.08]) and lower incidence of major bleeding events (1.4% versus 2.3%, HR, 0.65 [95% CI, 0.43–0.99]); however, these results were not reproduced in the subgroup analysis. Conclusions: The DCB strategy for successfully treated ACS cases achieved similar clinical outcomes to DES after 1 year. Further studies with an extended follow‐up are needed to confirm these results.
- Open Access
- 10 January 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (1) , 1-3
Circulation Reports Is Entering Its 7th Year With an Impact Factor
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 10 January 2025
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 7 (1) , 1-3
Open AccessCirculation Reports Is Entering Its 7th Year With an Impact Factor
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 1 December 2024
- Published by Japan Society for Vascular Failure in Vascular Failure
- Vol. 8 (1) , 24-34
A comprehensive retrospect on biomarkers indicating vascular failure
Atherosclerosis is characterized by the response of the vessel wall to chronic multifactorial injury, which leads to the formation of atheromatous or fibrous plaques. Endothelial dysfunction is the initial stage of atherosclerosis. In addition to endothelial dysfunction, smooth muscle dysfunction and metabolic abnormalities of the vessel wall, including inflammation, oxidative stress, and alterations in the neurohormonal balance, occur in various stages of atherosclerosis. 'Vascular failure' is defined as the integration of the aforementioned vascular abnormalities. In 2018, the Physiological Diagnosis Criteria for Vascular Failure Committee of the Japan Society of Vascular Failure and the Japanese Circulation Society proposed new physiological diagnostic criteria for vascular failure using universally available diagnostic modalities. However, these physiological tests can be performed only in large hospitals or specific cardiovascular clinics due to the requirement of expensive medical equipment and skillful technicians. BNP and/or NT-proBNP have emerged as useful biomarkers for evaluating the existence and severity of congestive heart failure, even by general physicians. However, distinct specific modalities such as cardiac sonography and MRI are essential to diagnose and treat heart failure. In this context, the Japan Society of Vascular Failure organized a working group to identify and establish suitable biomarkers for detecting vascular failure. In the 8th annual scientific meeting of the Japan Society for Vascular Failure, the working group held a symposium entitled "Possible biomarkers to detect vascular failure: What is known? What needs to be elucidated?" Herein, we elicit four presentations from the symposium and discuss them in detail.
- 1 December 2024
- Published by Japan Society for Vascular Failure in Vascular Failure
- Vol. 8 (1) , 24-34
Open AccessA comprehensive retrospect on biomarkers indicating vascular failure
Atherosclerosis is characterized by the response of the vessel wall to chronic multifactorial injury, which leads to the formation of atheromatous or fibrous plaques. Endothelial dysfunction is the initial stage of atherosclerosis. In addition to endothelial dysfunction, smooth muscle dysfunction and metabolic abnormalities of the vessel wall, including inflammation, oxidative stress, and alterations in the neurohormonal balance, occur in various stages of atherosclerosis. 'Vascular failure' is defined as the integration of the aforementioned vascular abnormalities. In 2018, the Physiological Diagnosis Criteria for Vascular Failure Committee of the Japan Society of Vascular Failure and the Japanese Circulation Society proposed new physiological diagnostic criteria for vascular failure using universally available diagnostic modalities. However, these physiological tests can be performed only in large hospitals or specific cardiovascular clinics due to the requirement of expensive medical equipment and skillful technicians. BNP and/or NT-proBNP have emerged as useful biomarkers for evaluating the existence and severity of congestive heart failure, even by general physicians. However, distinct specific modalities such as cardiac sonography and MRI are essential to diagnose and treat heart failure. In this context, the Japan Society of Vascular Failure organized a working group to identify and establish suitable biomarkers for detecting vascular failure. In the 8th annual scientific meeting of the Japan Society for Vascular Failure, the working group held a symposium entitled "Possible biomarkers to detect vascular failure: What is known? What needs to be elucidated?" Herein, we elicit four presentations from the symposium and discuss them in detail.
- Open Access
- 8 November 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (11) , 473-476
Message From the Editor-in-Chief ― Special Issue on the 30th Annual Scientific Meeting of the Japanese Association of Cardiac Rehabilitation ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 8 November 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (11) , 473-476
Open AccessMessage From the Editor-in-Chief ― Special Issue on the 30th Annual Scientific Meeting of the Japanese Association of Cardiac Rehabilitation ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 10 July 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (7) , 235-237
Message From the Editor-in-Chief ― Submission Campaign for Medical Staff ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 10 July 2024
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 6 (7) , 235-237
Open AccessMessage From the Editor-in-Chief ― Submission Campaign for Medical Staff ―
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.